A meta-analysis of 87,040 individuals identifies 23 new s cancer

Nature Genetics

46, 1103-1109

DOI: 10.1038/ng.3094

Citation Report

#	Article	IF	Citations
1	Genetic risk analysis goes global. Nature Reviews Urology, 2014, 11, 661-661.	1.9	0
2	Trans-ethnic genome-wide association studies: advantages and challenges of mapping in diverse populations. Genome Medicine, 2014, 6, 91.	3.6	167
3	Leveraging population admixture to characterize the heritability of complex traits. Nature Genetics, 2014, 46, 1356-1362.	9.4	69
4	Reevaluation of the BRCA2 truncating allele c.9976Aâ€‰>â€‰T (p.Lys3326Ter) in a familial breast cancer context. Scientific Reports, 2015, 5, 14800.	1.6	26
5	Functional annotation of HOT regions in the human genome: implications for human disease and cancer. Scientific Reports, 2015, 5, 11633.	1.6	24
6	Hard Work Ahead: Fine Mapping and Functional Follow-up of Susceptibility Alleles in Cancer GWAS. Current Epidemiology Reports, 2015, 2, 205-217.	1.1	1
7	The psychological impact of undergoing genetic-risk profiling in men with a family history of prostate cancer. Psycho-Oncology, 2015, 24, 1492-1499.	1.0	23
8	Systematic enrichment analysis of potentially functional regions for 103 prostate cancer risk-associated loci. Prostate, 2015, 75, 1264-1276.	1.2	37
9	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. Journal of the National Cancer Institute, 2015, 107, djv279.	3.0	152
10	Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate, 2015, 75, 1467-1474.	1.2	54
11	Do Health Professionals Need Additional Competencies for Stratified Cancer Prevention Based on Genetic Risk Profiling?. Journal of Personalized Medicine, 2015, 5, 191-212.	1.1	18
12	ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration. Frontiers in Aging Neuroscience, 2015, 7, 205.	1.7	17
13	Metabolomic analysis of prostate cancer risk in a prospective cohort: The alphaâ€tocopherol, betaâ€carotene cancer prevention (ATBC) study. International Journal of Cancer, 2015, 137, 2124-2132.	2.3	133
14	Prostate cancer trends in Barbados: An analysis of the Barbados Urologic Diseases Survey database. Cancer Epidemiology, 2015, 39, 825-830.	0.8	3
15	A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discovery, 2015, 5, 368-379.	7.7	56
17	Known susceptibility SNPs for sporadic prostate cancer show a similar association with â€œhereditaryâ€• prostate cancer. Prostate, 2015, 75, 474-483.	1.2	12
18	Vitamin D Receptor and RXR in the Postâ€Genomic Era. Journal of Cellular Physiology, 2015, 230, 758-766.	2.0	35
19	Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Human Genetics, 2015, 134, 439-450.	1.8	45

#	Article	IF	Citations
20	Epidemiology and Inherited Predisposition for Sporadic Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 619-640.	0.9	30
21	A simulated SNP experiment indicates a high risk of over-fitting and false positive results when a predictive multiple SNP model is established and tested within the same dataset. Radiotherapy and Oncology, 2015, 114, 310-313.	0.3	8
22	The genomic evolution of human prostate cancer. British Journal of Cancer, 2015, 113, 193-198.	2.9	51
23	Genetics of celiac disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 399-412.	1.0	39
24	Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. Human Molecular Genetics, 2015, 24, 5603-5618.	1.4	50
25	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1121-1129.	1.1	56
26	Genetics of Diabetic Nephropathy: a Long Road of Discovery. Current Diabetes Reports, 2015, 15, 41.	1.7	30
27	Two susceptibility loci identified for prostate cancer aggressiveness. Nature Communications, 2015, 6, 6889.	5.8	88
28	Replication and Heritability of Prostate Cancer Risk Variants: Impact of Population-Specific Factors. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 938-943.	1.1	13
29	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Human Molecular Genetics, 2015, 24, 5589-5602.	1.4	67
30	The Molecular Taxonomy of Primary Prostate Cancer. Cell, 2015, 163, 1011-1025.	13.5	2,435
31	Clinical Consultation Guide: How to Optimize the Use of Prostate-specific Antigen in the Current Era. European Urology Focus, 2015, 1, 149-151.	1.6	0
32	GNL3 and SKA3 are novel prostate cancer metastasis susceptibility genes. Clinical and Experimental Metastasis, 2015, 32, 769-782.	1.7	46
33	Impact of genetic similarity on imputation accuracy. BMC Genetics, 2015, 16, 90.	2.7	24
34	Large-scale association analysis in Asians identifies new susceptibility loci for prostate cancer. Nature Communications, 2015, 6, 8469.	5.8	51
35	Invited Commentary: Screening and the Elusive Etiology of Prostate Cancer. American Journal of Epidemiology, 2015, 182, 390-393.	1.6	14
36	Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. British Journal of Cancer, 2015, 113, 1086-1093.	2.9	32
37	Genome-Wide Association Study of Prostate Cancerâ€“Specific Survival. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1796-1800.	1.1	27

#	Article	IF	Citations
38	Prostate cancer screening in men aged 50â€“69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncology, The, 2015, 16, 1667-1676.	5.1	308
39	Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer. Asian Journal of Andrology, 2016, 18, 520.	0.8	36
40	Hereditary Prostate Cancer. , 2016, , 141-147.		1
41	Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus. Cancer Research, 2016, 76, 1916-1925.	0.4	7
42	Biomarkers for prostate cancer: present challenges and future opportunities. Future Science OA, 2016, 2, FSO72.	0.9	35
43	Germline genetic profiling in prostate cancer: latest developments and potential clinical applications. Future Science OA, 2016, 2, FSO87.	0.9	13
44	Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial. Prostate, 2016, 76, 1120-1129.	1.2	60
45	Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma. Prostate, 2016, 76, 479-490.	1.2	12
46	Comparing performance of modern genotype imputation methods in different ethnicities. Scientific Reports, 2016, 6, 34386.	1.6	49
47	Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors. Scientific Reports, 2016, 6, 39565.	1.6	15
48	Genetic predisposition to prostate cancer. British Medical Bulletin, 2016, 120, 75-89.	2.7	42
49	SNP interaction pattern identifier (SIPI): an intensive search for SNPâ€“SNP interaction patterns. Bioinformatics, 2017, 33, 822-833.	1.8	11
51	Putative Prostate Cancer Risk SNP in an Androgen Receptorâ€Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites. Human Mutation, 2016, 37, 52-64.	1.1	35
52	Genome-wide association study identifies five new susceptibility loci for primary angle closure glaucoma. Nature Genetics, 2016, 48, 556-562.	9.4	147
53	Inherited Variants in SULT1E1 and Response to Abiraterone Acetate by Men with Metastatic Castration Refractory Prostate Cancer. Journal of Urology, 2016, 196, 1112-1116.	0.2	12
54	Is birthweight associated with total and aggressive/lethal prostate cancer risks? A systematic review and meta-analysis. British Journal of Cancer, 2016, 114, 839-848.	2.9	16
55	Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 745-749.	1.1	23
56	Incorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 1718-1722.	0.8	1

#	Article	IF	Citations
57	Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. Cancer Research, 2016, 76, 5103-5114.	0.4	100
58	The Hunting of the Snark: Whither Genome-Wide Association Studies for Colorectal Cancer?. Gastroenterology, 2016, 150, 1528-1530.	0.6	4
59	WOMEN IN CANCER THEMATIC REVIEW: Diverse functions of DNA methylation: implications for prostate cancer and beyond. Endocrine-Related Cancer, 2016, 23, T169-T178.	1.6	8
60	Defining the Influence of Germline Variation on Metastasis Using Systems Genetics Approaches. Advances in Cancer Research, 2016, 132, 73-109.	1.9	3
61	Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium. British Journal of Cancer, 2016, 115, 624-631.	2.9	23
62	Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1449-1455.	1.1	43
63	Assessing the role of insulinâ€like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. International Journal of Cancer, 2016, 139, 1520-1533.	2.3	26
64	Spectrum of mitochondrial genomic variation and associated clinical presentation of prostate cancer in South African men. Prostate, 2016, 76, 349-358.	1.2	26
65	The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited. Prostate, 2016, 76, 897-904.	1.2	8
66	Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1456-1463.	1.1	22
67	Use of a Novel Nonparametric Version of DEPTH to Identify Genomic Regions Associated with Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1619-1624.	1.1	7
68	Familial prostate cancer. Seminars in Oncology, 2016, 43, 560-565.	0.8	49
69	Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nature Genetics, 2016, 48, 1142-1150.	9.4	196
70	Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance. Carcinogenesis, 2016, 37, 965-971.	1.3	4
71	Mendelian randomization study of adiposity-related traits and risk of breast, ovarian, prostate, lung and colorectal cancer. International Journal of Epidemiology, 2016, 45, 896-908.	0.9	124
72	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
73	Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somaticTMPRSS2:ERGfusion status. Human Molecular Genetics, 2016, 25, ddw349.	1.4	8
74	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nature Communications, 2016, 7, 10979.	5.8	50

#	Article	IF	Citations
75	4C-seq revealed long-range interactions of a functional enhancer at the 8q24 prostate cancer risk locus. Scientific Reports, 2016, 6, 22462.	1.6	30
76	Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma. Nature Communications, 2016, 7, 12510.	5.8	94
77	What's new in screening in 2015?. Current Opinion in Urology, 2016, 26, 447-458.	0.9	10
78	Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness. BJU International, 2016, 118, 646-653.	1.3	31
79	Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. Human Genetics, 2016, 135, 923-938.	1.8	37
80	The contribution of rare variation to prostate cancer heritability. Nature Genetics, 2016, 48, 30-35.	9.4	139
81	Calcium can mobilize and activate myosin-VI. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1162-9.	3.3	41
82	Personalized testing based on polygenic risk score is promising for more efficient population-based screening programs for common oncological diseases. Annals of Oncology, 2016, 27, 369-370.	0.6	5
83	Quantifying the utility of single nucleotide polymorphisms to guide colorectal cancer screening. Future Oncology, 2016, 12, 503-513.	1.1	42
84	Radiogenomics â€“ current status, challenges and future directions. Cancer Letters, 2016, 382, 127-136.	3.2	70
85	Mutational Landscape of Aggressive Prostate Tumors in African American Men. Cancer Research, 2016, 76, 1860-1868.	0.4	61
86	Sports genetics moving forward: lessons learned from medical research. Physiological Genomics, 2016, 48, 175-182.	1.0	26
87	Gene regulatory mechanisms underpinning prostate cancer susceptibility. Nature Genetics, 2016, 48, 387-397.	9.4	119
88	Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. British Journal of Cancer, 2016, 114, 945-952.	2.9	17
89	Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. JAMA - Journal of the American Medical Association, 2016, 315, 68.	3.8	648
90	Whole-exome sequencing of over 4100 men of African ancestry and prostate cancer risk. Human Molecular Genetics, 2016, 25, 371-381.	1.4	26
91	Multigene panels in prostate cancer risk assessment: a systematic review. Genetics in Medicine, 2016, 18, 535-544.	1.1	11
92	Single nucleotide polymorphisms in clinics: Fantasy or reality for cancer?. Critical Reviews in Clinical Laboratory Sciences, 2016, 53, 29-39.	2.7	71

#	Article	IF	Citations
93	Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. Clinical Cancer Research, 2016, 22, 448-458.	3.2	29
94	Is the Genetic Background of Co-Stimulatory CD28/CTLA-4 Pathway the Risk Factor for Prostate Cancer?. Pathology and Oncology Research, 2017, 23, 837-843.	0.9	5
95	Management of Prostate Cancer. , 2017, , .		5
96	New insights into the genetics of primary open-angle glaucoma based on meta-analyses of intraocular pressure and optic disc characteristics.. Human Molecular Genetics, 2017, 26, ddw399.	1.4	120
97	Identifying aggressive prostate cancer foci using a DNA methylation classifier. Genome Biology, 2017, 18, 3.	3.8	43
98	Individual and Population-Based Screening. , 2017, , 43-55.		0
99	Epidemiology of Prostate Cancer in Europe: Patterns, Trends and Determinants. , 2017, , 1-27.		10
100	Genomeâ€wide twoâ€locus interaction analysis identifies multiple epistatic SNP pairs that confer risk of prostate cancer: A crossâ€population study. International Journal of Cancer, 2017, 140, 2075-2084.	2.3	10
101	Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases. JAMA Oncology, 2017, 3, 636.	3.4	376
102	Exome Array Analysis Identifies Variants in SPOCD1 and BTN3A2 That Affect Risk for Gastric Cancer. Gastroenterology, 2017, 152, 2011-2021.	0.6	58
103	Estimating Heritability of Prostate Cancerâ€Specific Survival Using Populationâ€Based Registers. Prostate, 2017, 77, 900-907.	1.2	3
104	GeneImp: Fast Imputation to Large Reference Panels Using Genotype Likelihoods from Ultralow Coverage Sequencing. Genetics, 2017, 206, 91-104.	1.2	38
105	A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations. Current Opinion in Urology, 2017, 27, 475-480.	0.9	3
106	Prostate cancer incidence as an iceberg. European Journal of Epidemiology, 2017, 32, 477-479.	2.5	0
107	Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci. Nature Genetics, 2017, 49, 993-1004.	9.4	114
108	Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	13
109	Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project. Journal of Epidemiology, 2017, 27, S65-S70.	1.1	11
110	Genetic variants associated with mosaic Y chromosome loss highlight cell cycle genes and overlap with cancer susceptibility. Nature Genetics, 2017, 49, 674-679.	9.4	117

#	Article	IF	Citations
111	Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network. Scientific Reports, 2017, 7, 738.	1.6	12
112	Interactions Between Genome-Wide Significant Genetic Variants and Circulating Concentrations of 25-Hydroxyvitamin D in Relation to Prostate Cancer Risk in the National Cancer Institute BPC3. American Journal of Epidemiology, 2017, 185, 452-464.	1.6	11
113	Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. European Urology, 2017, 71, 740-747.	0.9	256
114	Genome-wide association studies of cancer: current insights and future perspectives. Nature Reviews Cancer, 2017, 17, 692-704.	12.8	285
116	African-American Prostate Cancer Disparities. Current Urology Reports, 2017, 18, 81.	1.0	77
117	Big data in cancer genomics. Current Opinion in Systems Biology, 2017, 4, 78-84.	1.3	12
118	Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial. Prostate, 2017, 77, 1179-1186.	1.2	9
119	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. British Journal of Cancer, 2017, 117, 734-743.	2.9	7
120	Cohort Profile: The Melbourne Collaborative Cohort Study (Health 2020). International Journal of Epidemiology, 2017, 46, 1757-1757i.	0.9	123
121	Integration of Genome Scale Metabolic Networks and Gene Regulation of Metabolic Enzymes With Physiologically Based Pharmacokinetics. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 732-746.	1.3	17
122	A microsatellite repeat in PCA3 long non-coding RNA is associated with prostate cancer risk and aggressiveness. Scientific Reports, 2017, 7, 16862.	1.6	12
123	Cis-SNPs Set Testing and PrediXcan Analysis for Gene Expression Data using Linear Mixed Models. Scientific Reports, 2017, 7, 15237.	1.6	6
124	Directional Transportation of Assembled Molecular Linear Motors. , 2017, , 205-235.		1
125	A Prostate Cancer Risk Element Functions as a Repressive Loop that Regulates HOXA13. Cell Reports, 2017, 21, 1411-1417.	2.9	68
126	Integration of VDR genome wide binding and GWAS genetic variation data reveals co-occurrence of VDR and NF-Î¹B binding that is linked to immune phenotypes. BMC Genomics, 2017, 18, 132.	1.2	35
127	Genetic pleiotropy between age-related macular degeneration and 16 complex diseases and traits. Genome Medicine, 2017, 9, 29.	3.6	52
128	Inherited determinants of early recurrent somatic mutations in prostate cancer. Nature Communications, 2017, 8, 48.	5.8	23
129	Genomes of early onset prostate cancer. Current Opinion in Urology, 2017, 27, 481-487.	0.9	9

#	Article	IF	Citations
130	Epidemiology of Prostate Cancer. , 2017, , 107-125.		3
131	Estimation of heritability for nine common cancers using data from genomeâ€wide association studies in Chinese population. International Journal of Cancer, 2017, 140, 329-336.	2.3	66
132	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 126-135.	1.1	278
133	Crucial role of noncoding RNA in driving prostate cancer development and progression. Epigenomics, 2017, 9, 1-3.	1.0	4
134	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. International Journal of Cancer, 2017, 140, 75-85.	2.3	28
135	Impact of the G84E variant on HOXB13 gene and protein expression in formalin-fixed, paraffin-embedded prostate tumours. Scientific Reports, 2017, 7, 17778.	1.6	8
136	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. Journal of the National Cancer Institute, 2017, 109, .	3.0	57
137	Validation of the novel susceptibility loci for prostate cancer in a Chinese population. Oncology Letters, 2017, 15, 2567-2573.	0.8	3
138	Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study. BMJ: British Medical Journal, 2017, 359, j4761.	2.4	126
139	The role of CYP17A1 in prostate cancer development: structure, function, mechanism of action, genetic variations and its inhibition. General Physiology and Biophysics, 2017, 36, 487-499.	0.4	29
141	Exploration of the molecular mechanism of prostate cancer based on mRNA and miRNA expression profiles. OncoTargets and Therapy, 2017, Volume 10, 3225-3232.	1.0	11
142	The Mediterranean Diet Reduces the Risk and Mortality of the Prostate Cancer: A Narrative Review. Frontiers in Nutrition, 2017, 4, 38.	1.6	47
143	Molecular Pathology of Prostate Cancer. , 2017, , 271-286.		2
144	Genomics of Cardiometabolic Disorders in Sub-Saharan Africa. Public Health Genomics, 2017, 20, 9-26.	0.6	17
145	Whole exome sequencing in 75 high-risk families with validation and replication in independent case-control studies identifies TANGO2, OR5H14, and CHAD as new prostate cancer susceptibility genes. Oncotarget, 2017, 8, 1495-1507.	0.8	11
146	Improvement in prediction of prostate cancer prognosis with somatic mutational signatures. Journal of Cancer, 2017, 8, 3261-3267.	1.2	33
147	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	0.8	152
149	Prostate Cancer Risk: Single Nucleotide Polymorphisms (SNPs). Molecular Pathology Library, 2018, , 117-128.	0.1	0

#	Article	IF	Citations
150	Metabolomic-Based Stratification in Prostate Cancer. Molecular Pathology Library, 2018, , 237-258.	0.1	1
151	Re: Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. European Urology, 2018, 74, 397.	0.9	1
152	The miRNA-kallikrein interaction: a mosaic of epigenetic regulation in cancer. Biological Chemistry, 2018, 399, 973-982.	1.2	4
153	Genome-Wide Association Studies in Glioma. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 418-428.	1.1	34
154	Genetic risk of prostate cancer in Ugandan men. Prostate, 2018, 78, 370-376.	1.2	31
155	Precision Molecular Pathology of Hodgkin Lymphoma. Molecular Pathology Library, 2018, , .	0.1	2
156	The Epidemiology of Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030361.	2.9	461
157	Molecular Biomarkers in the Clinical Management of Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030601.	2.9	11
158	Circadian pathway genetic variation and cancer risk: evidence from genome-wide association studies. BMC Medicine, 2018, 16, 20.	2.3	71
159	Genome-Wide Association Studies of Cancer in Diverse Populations. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 405-417.	1.1	57
160	Prostate Cancer Germline Variations and Implications for Screening and Treatment. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030379.	2.9	25
161	Genetic factors influencing prostate cancer risk in Norwegian men. Prostate, 2018, 78, 186-192.	1.2	11
162	The Epidemiology of Hodgkin Lymphoma. Molecular Pathology Library, 2018, , 157-196.	0.1	2
163	Analysis of Tumor Biology to Advance Cancer Health Disparity Research. American Journal of Pathology, 2018, 188, 304-316.	1.9	24
164	Genomic Markers in Prostate Cancer Decision Making. European Urology, 2018, 73, 572-582.	0.9	201
165	Leveraging Human Genetics to Guide Cancer Drug Development. JCO Clinical Cancer Informatics, 2018, 2, 1-11.	1.0	3
166	Association Analysis of a Microsatellite Repeat in the TRIB1 Gene With Prostate Cancer Risk, Aggressiveness and Survival. Frontiers in Genetics, 2018, 9, 428.	1.1	24
168	Western Dietary Pattern, But not Mediterranean Dietary Pattern, Increases the Risk of Prostate Cancer. Nutrition and Cancer, 2018, 70, 851-859.	0.9	23

#	Article	IF	Citations
169	Large-scale transcriptome-wide association study identifies new prostate cancer risk regions. Nature Communications, 2018, 9, 4079.	5.8	121
170	CRISPR-mediated deletion of prostate cancer risk-associated CTCF loop anchors identifies repressive chromatin loops. Genome Biology, 2018, 19, 160.	3.8	60
172	Whole-Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-NaÃ¯ve, High-Risk Prostate Cancer. Cancer Research, 2018, 78, 6736-6746.	0.4	66
173	Ageâ€specific genomeâ€wide association study in glioblastoma identifies increased proportion of â€˜lower grade gliomaâ€™â€like features associated with younger age. International Journal of Cancer, 2018, 143, 2359-2366.	2.3	21
174	Cancer genetics, precision prevention and a call to action. Nature Genetics, 2018, 50, 1212-1218.	9.4	94
175	From genome-wide associations to candidate causal variants by statistical fine-mapping. Nature Reviews Genetics, 2018, 19, 491-504.	7.7	611
176	Genotype Imputation from Large Reference Panels. Annual Review of Genomics and Human Genetics, 2018, 19, 73-96.	2.5	158
177	The personal and clinical utility of polygenic risk scores. Nature Reviews Genetics, 2018, 19, 581-590.	7.7	1,102
178	Genetic Polymorphism Analysis in Predicting Prognosis of Advanced Prostate Cancer. , 2018, , 175-187.		0
179	Molecular Subtypes of Prostate Cancer. Current Oncology Reports, 2018, 20, 58.	1.8	77
180	Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score. Prostate, 2018, 78, 1063-1068.	1.2	1
181	Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease. British Journal of Cancer, 2018, 119, 96-104.	2.9	40
182	Heritable methylation marks associated with breast and prostate cancer risk. Prostate, 2018, 78, 962-969.	1.2	15
183	Genome-wide Association Study (GWAS) of Germline Copy Number Variations (CNVs) Reveal Genetic Risks of Prostate Cancer in Chinese population. Journal of Cancer, 2018, 9, 923-928.	1.2	13
184	Germline mutations in PPFIBP2 are associated with lethal prostate cancer. Prostate, 2018, 78, 1222-1228.	1.2	12
185	Molecular Epidemiology and Cancer Risk â€ . , 2018, , 487-487.		0
186	Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival. European Urology, 2018, 74, 710-719.	0.9	47
187	Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities. International Journal of Molecular Sciences, 2018, 19, 1255.	1.8	50

#	Article	IF	Citations
188	Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus. Cell, 2018, 174, 576-589.e18.	13.5	116
189	Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19. Cell, 2018, 174, 564-575.e18.	13.5	264
190	Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survival. Carcinogenesis, 2018, 39, 879-888.	1.3	9
191	Omics, big data and machine learning as tools to propel understanding of biological mechanisms and to discover novel diagnostics and therapeutics. Metabolism: Clinical and Experimental, 2018, 87, A1-A9.	1.5	83
192	A Review of Prostate Cancer Genome-Wide Association Studies (GWAS). Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 845-857.	1.1	118
193	Classification of Prostate Cancer Patients and Healthy Individuals by Means of a Hybrid Algorithm Combing SVM and Evolutionary Algorithms. Lecture Notes in Computer Science, 2018, , 547-557.	1.0	1
194	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	9.4	652
195	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	5.8	88
197	Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanisms. Nature Communications, 2019, 10, 3107.	5.8	28
198	The prostate cancer risk variant rs55958994 regulates multiple gene expression through extreme long-range chromatin interaction to control tumor progression. Science Advances, 2019, 5, eaaw6710.	4.7	35
199	Reconstitution reveals how myosin-VI self-organises to generate a dynamic mechanism of membrane sculpting. Nature Communications, 2019, 10, 3305.	5.8	8
200	Mesenchymal stem cell-mediated delivery of therapeutic adenoviral vectors to prostate cancer. Stem Cell Research and Therapy, 2019, 10, 190.	2.4	30
201	The Human TET2 Gene Contains Three Distinct Promoter Regions With Differing Tissue and Developmental Specificities. Frontiers in Cell and Developmental Biology, 2019, 7, 99.	1.8	8
202	Genome-Wide Association Studies. , 2019, , .		7
203	Prostate Cancer: How Nurse Practitioners Can Aid in Disease Diagnosis and Management. , 2019, 23, 247-250.		0
204	Liquid Biopsy in Oligometastatic Prostate Cancerâ€"A Biologist's Point of View. Frontiers in Oncology, 2019, 9, 775.	1.3	21
205	A high-resolution 3D epigenomic map reveals insights into the creation of the prostate cancer transcriptome. Nature Communications, 2019, 10, 4154.	5.8	87
206	12 new susceptibility loci for prostate cancer identified by genome-wide association study in Japanese population. Nature Communications, 2019, 10, 4422.	5.8	49

#	Article	IF	Citations
207	The <scp>MYO</scp>6 interactome: selective motorâ€cargo complexes for diverse cellular processes. FEBS Letters, 2019, 593, 1494-1507.	1.3	28
208	Genetic associations of breast and prostate cancer are enriched for regulatory elements identified in disease-related tissues. Human Genetics, 2019, 138, 1091-1104.	1.8	7
209	Cross-population analysis for functional characterization of type II diabetes variants. BMC Bioinformatics, 2019, 20, 320.	1.2	2
210	Achieving World Class. Journal - American Water Works Association, 2019, 111, 58-61.	0.2	0
211	The role of <scp>HLA</scp> variation in lymphoma aetiology and survival. Journal of Internal Medicine, 2019, 286, 154-180.	2.7	16
212	Concept and benchmarks for assessing narrowâ€sense validity of genetic risk score values. Prostate, 2019, 79, 1099-1105.	1.2	18
213	Identification of Novel Susceptibility Loci and Genes for Prostate Cancer Risk: A Transcriptome-Wide Association Study in Over 140,000 European Descendants. Cancer Research, 2019, 79, 3192-3204.	0.4	43
214	Outcomes of universal germline testing for men with prostate cancer in an Australian tertiary center. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 257-261.	0.7	5
215	Cross-Cancer Pleiotropic Associations with Lung Cancer Risk in African Americans. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 715-723.	1.1	11
216	An Overview of the Polymorphisms of Circadian Genes Associated With Endocrine Cancer. Frontiers in Endocrinology, 2019, 10, 104.	1.5	48
217	SummaryAUC: a tool for evaluating the performance of polygenic risk prediction models in validation datasets with only summary level statistics. Bioinformatics, 2019, 35, 4038-4044.	1.8	15
218	Genetic counseling, 2030: An onâ€demand service tailored to the needs of a price conscious, genetically literate, and busy world. Journal of Genetic Counseling, 2019, 28, 456-465.	0.9	14
219	An expanded variant list and assembly annotation identifies multiple novel coding and noncoding genes for prostate cancer risk using a normal prostate tissue eQTL data set. PLoS ONE, 2019, 14, e0214588.	1.1	5
220	Systematic evaluation of cancerâ€specific genetic risk score for 11 types of cancer in The Cancer Genome Atlas and Electronic Medical Records and Genomics cohorts. Cancer Medicine, 2019, 8, 3196-3205.	1.3	22
221	Mechanistic insights into Nav1.7â€dependent regulation of rat prostate cancer cell invasiveness revealed by toxin probes and proteomic analysis. FEBS Journal, 2019, 286, 2549-2561.	2.2	17
222	Current progress and questions in germline genetics of prostate cancer. Asian Journal of Urology, 2019, 6, 3-9.	0.5	11
223	An exome-wide rare variant analysis of Korean men identifies three novel genes predisposing to prostate cancer. Scientific Reports, 2019, 9, 17173.	1.6	6
224	Genomics of Cardiometabolic Disorders in Sub-Saharan Africa. , 2019, , 168-198.		0

#	Article	IF	Citations
225	Pre-diagnostic Serum Metabolomic Profiling of Prostate Cancer Survival. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 853-859.	1.7	21
226	Current perspectives in assessing humoral immunity after measles vaccination. Expert Review of Vaccines, 2019, 18, 75-87.	2.0	39
227	An AR-ERG transcriptional signature defined by long-range chromatin interactomes in prostate cancer cells. Genome Research, 2019, 29, 223-235.	2.4	46
228	Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients. Cancer Medicine, 2019, 8, 1110-1123.	1.3	69
229	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 208-216.	1.1	21
230	Discovery of common and rare genetic risk variants for colorectal cancer. Nature Genetics, 2019, 51, 76-87.	9.4	377
231	A genomeâ€wide association study of prostate cancer in Latinos. International Journal of Cancer, 2020, 146, 1819-1826.	2.3	24
232	Functional deficiency of DNA repair gene EXO5 results in androgen-induced genomic instability and prostate tumorigenesis. Oncogene, 2020, 39, 1246-1259.	2.6	8
233	Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data. Annual Review of Pharmacology and Toxicology, 2020, 60, 333-352.	4.2	39
234	Comparison of the roles of estrogens and androgens in breast cancer and prostate cancer. Journal of Cellular Biochemistry, 2020, 121, 2756-2769.	1.2	11
235	Disparities in prostate cancer incidence and mortality rates: Solvable or not?. Prostate, 2020, 80, 3-16.	1.2	30
236	Pleiotropy in eye disease and related traits. , 2020, , 315-336.		2
237	An epigenome-wide association study of sex-specific chronological ageing. Genome Medicine, 2020, 12, 1.	3.6	117
238	Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT. Prostate Cancer and Prostatic Diseases, 2020, 23, 333-342.	2.0	10
239	Impact of a Changing Population Structure and Clustering of Cancer in Prostate Cancer Patients Depending on a First-Degree Family History. Urologia Internationalis, 2020, 104, 222-229.	0.6	3
240	Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications. International Journal of Molecular Sciences, 2020, 21, 5036.	1.8	38
241	An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. Nature Communications, 2020, 11, 3905.	5.8	28
242	Recent Advancements in Biomarkers and Early Detection of Gastrointestinal Cancers. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , .	0.2	1

#	Article	IF	Citations
243	NCOR1 may be a potential biomarker of a novel molecular subtype of prostate cancer. FEBS Open Bio, 2020, 10, 2678-2686.	1.0	1
244	Validation of a prostate cancer polygenic risk score. Prostate, 2020, 80, 1314-1321.	1.2	23
245	Association between systemic sclerosis and risk of lung cancer: results from a pool of cohort studies and Mendelian randomization analysis. Autoimmunity Reviews, 2020, 19, 102633.	2.5	7
246	Survival outcomes in men with a positive family history of prostate cancer: a registry based study. BMC Cancer, 2020, 20, 894.	1.1	11
247	Germline mutations and prostate cancer: is it time to change treatment algorithms?. Chinese Clinical Oncology, 2020, 9, 65-65.	0.4	2
248	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. Cancers, 2020, 12, 3254.	1.7	16
249	Genome-wide association study of germline copy number variations reveals an association with prostate cancer aggressiveness. Mutagenesis, 2020, 35, 283-290.	1.0	3
250	A Custom Genotyping Array Reveals Population-Level Heterogeneity for the Genetic Risks of Prostate Cancer and Other Cancers in Africa. Cancer Research, 2020, 80, 2956-2966.	0.4	25
251	Population Differentiation at the PVT1 Gene Locus: Implications for Prostate Cancer. G3: Genes, Genomes, Genetics, 2020, 10, 2257-2264.	0.8	8
252	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology, 2020, 38, 2798-2811.	0.8	170
253	Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants. Nature Communications, 2020, 11, 1217.	5.8	46
254	DNA methylation and cis-regulation of gene expression by prostate cancer risk SNPs. PLoS Genetics, 2020, 16, e1008667.	1.5	15
255	The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial. PLoS Medicine, 2020, 17, e1003033.	3.9	6
256	Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry. PLoS Genetics, 2020, 16, e1008641.	1.5	78
257	Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB. Human Molecular Genetics, 2020, 29, 1581-1591.	1.4	8
258	Cognitive disorders associated with hospitalization of COVID-19: Results from an observational cohort study. Brain, Behavior, and Immunity, 2021, 91, 383-392.	2.0	44
259	Ethnic variation in prostate cancer detection: a feasibility study for use of the Stockholm3 test in a multiethnic U.S. cohort. Prostate Cancer and Prostatic Diseases, 2021, 24, 120-127.	2.0	5
260	Photodynamic therapy for prostate cancer â€“ A narrative review. Photodiagnosis and Photodynamic Therapy, 2021, 33, 102158.	1.3	34

#	Article	IF	Citations
261	Validation of prostate cancer risk variants rs10993994 and rs7098889 by CRISPR/Cas9 mediated genome editing. Gene, 2021, 768, 145265.	1.0	10
262	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	9.4	264
263	Susceptibility-Associated Genetic Variation in NEDD9 Contributes to Prostate Cancer Initiation and Progression. Cancer Research, 2021, 81, 3766-3776.	0.4	4
265	Family history of prostate cancer and prostate tumor aggressiveness in black and non-black men;results from an equal access biopsy study. Cancer Causes and Control, 2021, 32, 337-346.	0.8	3
266	Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease. Cancers, 2021, 13, 760.	1.7	22
268	Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management. Cancers, 2021, 13, 2154.	1.7	13
269	Comprehensive Analysis of Multiple Cohort Datasets Deciphers the Utility of Germline Single-Nucleotide Polymorphisms in Prostate Cancer Diagnosis. Cancer Prevention Research, 2021, 14, 741-752.	0.7	4
270	Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. European Urology, 2021, 79, 519-529.	0.9	30
272	Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease. Prostate Cancer and Prostatic Diseases, 2021, 24, 1158-1166.	2.0	5
273	NRG1 Genetic Variant Influences the Efficacy of Androgen-Deprivation Therapy in Men with Prostate Cancer. Biomedicines, 2021, 9, 528.	1.4	2
274	The role of single nucleotide polymorphisms of miRNAs 100 and 146a as prognostic factors for prostate cancer. International Journal of Biological Markers, 2021, 36, 50-56.	0.7	5
275	Copy Number Profiles of Prostate Cancer in Men of Middle Eastern Ancestry. Cancers, 2021, 13, 2363.	1.7	1
276	Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study. BJU International, 2021, 128, 702-712.	1.3	0
277	Plasma Metabolomics for Discovery of Early Metabolic Markers of Prostate Cancer Based on Ultra-High-Performance Liquid Chromatography-High Resolution Mass Spectrometry. Cancers, 2021, 13, 3140.	1.7	10
278	Structural model for formation of packages of clinical and diagnostic tests to organize personalized medical care for patients with malignant tumors of the prostate gland. Rossiiskii Meditsinskii Zhurnal: Organ Ministerstva Zdravookhraneniia RSFSR, 2021, 27, 45-55.	0.1	0
279	Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine. Journal of Personalized Medicine, 2021, 11, 664.	1.1	11
280	The genetic architecture of temperature adaptation is shaped by population ancestry and not by selection regime. Genome Biology, 2021, 22, 211.	3.8	11
281	African Global Representation in Biomedical Sciences. Annual Review of Biomedical Data Science, 2021, 4, 57-81.	2.8	3

#	Article	IF	Citations
282	Parallel Reporter Assays Identify Altered Regulatory Role of rs684232 in Leading to Prostate Cancer Predisposition. International Journal of Molecular Sciences, 2021, 22, 8792.	1.8	9
283	Germline Predisposition to Prostate Cancer in Diverse Populations. Urologic Clinics of North America, 2021, 48, 411-423.	0.8	6
284	Integrative Epigenome Map of the Normal Human Prostate Provides Insights Into Prostate Cancer Predisposition. Frontiers in Cell and Developmental Biology, 2021, 9, 723676.	1.8	5
285	Genetically Informed Prostate Cancer Screening. Urologic Clinics of North America, 2021, 48, 373-386.	0.8	1
286	Polygenic Risk Scores in Prostate Cancer Risk Assessment and Screening. Urologic Clinics of North America, 2021, 48, 387-399.	0.8	7
287	Association between Artificial Light at Night Exposure and breast and prostate cancer risk â€“ the review. Journal of Education, Health and Sport, 2021, 11, 148-160.	0.0	2
288	Translating polygenic risk scores for clinical use by estimating the confidence bounds of risk prediction. Nature Communications, 2021, 12, 5276.	5.8	12
289	Differential methylation of genes in the human placenta associated with bisphenol A exposure. Environmental Research, 2021, 200, 111389.	3.7	11
290	Hybrid algorithm for the classification of prostate cancer patients of the MCC-Spain study based on support vector machines and genetic algorithms. Neurocomputing, 2021, 452, 386-394.	3.5	3
293	Pleiotropy-robust Mendelian randomization. International Journal of Epidemiology, 2018, 47, 1279-1288.	0.9	66
299	Pan-Cancer Analyses of the Nuclear Receptor Superfamily. Nuclear Receptor Research, 2015, 2, .	2.5	40
300	Winner's Curse Correction and Variable Thresholding Improve Performance of Polygenic Risk Modeling Based on Genome-Wide Association Study Summary-Level Data. PLoS Genetics, 2016, 12, e1006493.	1.5	98
301	Germline Variants of Prostate Cancer in Japanese Families. PLoS ONE, 2016, 11, e0164233.	1.1	21
302	Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Oncotarget, 2016, 7, 57011-57020.	0.8	41
303	Next generation mapping reveals novel large genomic rearrangements in prostate cancer. Oncotarget, 2017, 8, 23588-23602.	0.8	43
304	Exome-based genome-wide association study and risk assessment using genetic risk score to prostate cancer in the Korean population. Oncotarget, 2017, 8, 43934-43943.	0.8	7
305	Deletion of tumor suppressors adenomatous polyposis coli and Smad4 in murine luminal epithelial cells causes invasive prostate cancer and loss of androgen receptor expression. Oncotarget, 2017, 8, 80265-80277.	0.8	7
306	Genetic risk score to predict biochemical recurrence after radical prostatectomy in prostate cancer: prospective cohort study. Oncotarget, 2017, 8, 75979-75988.	0.8	6

#	Article	IF	Citations
307	Network-directed cis-mediator analysis of normal prostate tissue expression profiles reveals downstream regulatory associations of prostate cancer susceptibility loci. Oncotarget, 2017, 8, 85896-85908.	0.8	2
308	Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer. Oncotarget, 2020, 11, 1321-1333.	0.8	10
309	A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population. Oncotarget, 2016, 7, 21393-21403.	0.8	18
310	Heritability of prostate cancer: a tale of rare variants and common single nucleotide polymorphisms. Annals of Translational Medicine, 2016, 4, 206-206.	0.7	16
311	The PLCO Biorepository: Creating, Maintaining, and Administering a Unique Biospecimen Resource. Reviews on Recent Clinical Trials, 2015, 10, 212-222.	0.4	21
312	Admixture Mapping Links RACGAP1 Regulation to Prostate Cancer in African Americans. Cancer Genomics and Proteomics, 2018, 15, 185-191.	1.0	5
313	Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, Down-Regulates VEGF and Induces Apoptosis in Prostate Cancer Cells. Iranian Biomedical Journal, 2019, 23, 312-323.	0.4	10
314	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. Health Technology Assessment, 2020, 24, 1-176.	1.3	22
315	A comparison of genetic risk score with family history for estimating prostate cancer risk. Asian Journal of Andrology, 2016, 18, 515.	0.8	11
316	Personalized prostate cancer care: from screening to treatment. Asian Journal of Andrology, 2016, 18, 505.	0.8	8
317	Clinical validity and utility of genetic risk scores in prostate cancer. Asian Journal of Andrology, 2016, 18, 509.	0.8	28
318	Haplotypes spanning centromeric regions reveal persistence of large blocks of archaic DNA. ELife, 2019, 8, .	2.8	54
319	An examination of clinical differences between carriers and non-carriers of chromosome 8q24 risk alleles in a New Zealand Caucasian population with prostate cancer. PeerJ, 2016, 4, e1731.	0.9	2
320	The Role of RNASEL Mutation in the Complex Genetic Landscape of Prostate Adenocarcinoma. Gene, Cell and Tissue, 2014, 1, .	0.2	0
323	Can We Screen and Still Reduce Overdiagnosis?. Current Clinical Urology, 2018, , 9-20.	0.0	0
324	Epidemiology, Energy Balance and Prostate Cancer Incidence and Mortality. Energy Balance and Cancer, 2018, , 1-20.	0.2	0
325	Prognostic and predictive biomarkers of prostate cancer. Onkourologiya, 2018, 13, 111-121.	0.1	3
329	The Association of Single Nucleotide Polymorphisms with Cancer Risk. , 2019, , 87-144.		0

#	Article	IF	Citations
330	Genetic Risk Score for Prostate Cancer in the Romanian Population. Romanian Biotechnological Letters, 2019, 24, 100-107.	0.5	0
333	The prospect of discovering new biomarkers for ovarian cancer based on current knowledge of¿½susceptibility loci and genetic variation (Review). International Journal of Molecular Medicine, 2019, 44, 1599-1608.	1.8	2
335	MODERN CONCEPTS OF THE MOLECULAR GENETIC MARKERS OF PROSTATE CANCER. Siberian Journal of Oncology, 2021, 20, 162-169.	0.1	0
336	Genetische Einflussfaktoren des Krebsrisikos. Springer Reference Medizin, 2020, , 1-7.	0.0	0
337	Genetic Marker Identification for the Detection of Early-Onset Gastric Cancer Through Genome-Wide Association Studies. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 191-211.	0.2	0
338	Genetic Contributions to Prostate Cancer Disparities in Men of West African Descent. Frontiers in Oncology, 2021, 11, 770500.	1.3	10
340	Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, Down-Regulates VEGF and Induces Apoptosis in Prostate Cancer Cells. Iranian Biomedical Journal, 2019, 23, 312-23.	0.4	3
341	Induction of apoptosis and modulation of homologous recombination DNA repair pathway in prostate cancer cells by the combination of AZD2461 and valproic acid. EXCLI Journal, 2019, 18, 485-498.	0.5	2
342	Diversity on demand: multi-ancestry meta-analysis improves genetic risk prediction in prostate cancer. American Journal of Clinical and Experimental Urology, 2021, 9, 189-193.	0.4	1
343	Genetics of prostate cancer and its utility in treatment and screening. Advances in Genetics, 2021, 108, 147-199.	0.8	3
344	Prostate Cancer in Lebanon: Incidence, Temporal Trends, and Comparison to Countries From Different Regions in the World. Cancer Control, 2021, 28, 107327482110552.	0.7	3
345	Racial Differences in Prostate Cancer Characteristics and Cancer-Specific Mortality: An Overview. World Journal of Men?s Health, 2022, 40, 217.	1.7	19
346	Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling. Genome Medicine, 2022, 14, 9.	3.6	14
347	Do sex hormones confound or mediate the effect of chronotype on breast and prostate cancer? A Mendelian randomization study. PLoS Genetics, 2022, 18, e1009887.	1.5	14
348	Prostate Cancer Susceptibility Loci Identified in GATA2 and ZMIZ1 in Chinese Population. International Journal of Genomics, 2022, 2022, 1-6.	0.8	5
350	A microRNA Transcriptome-wide Association Study of Prostate Cancer Risk. Frontiers in Genetics, 2022, 13, 836841.	1.1	3
352	Genetic variant located on chromosome 17p12 contributes to prostate cancer onset and biochemical recurrence. Scientific Reports, 2022, 12, 4546.	1.6	2
353	Applying Mendelian randomization to appraise causality in relationships between nutrition and cancer. Cancer Causes and Control, 2022, 33, 631-652.	0.8	7

#	Article	IF	Citations
354	PITX1 Is a Regulator of TERT Expression in Prostate Cancer with Prognostic Power. Cancers, 2022, 14, 1267.	1.7	7
355	Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies. Prostate Cancer and Prostatic Diseases, 2022, 25, 422-430.	2.0	12
356	Long Non-Coding RNAs at the Chromosomal Risk Loci Identified by Prostate and Breast Cancer GWAS. Genes, 2021, 12, 2028.	1.0	5
357	Genome-Wide Association Study of Fluorescent Oxidation Products Accounting for Tobacco Smoking Status in Adults from the French EGEA Study. Antioxidants, 2022, 11, 802.	2.2	3
361	The role of MTNR1B polymorphism on circadian rhythmâ€related cancer: A <scp>UK</scp> Biobank cohort study. International Journal of Cancer, 2022, 151, 888-896.	2.3	3
363	Discrimination of Patients with Prostate Cancer from Healthy Persons Using a Set of Single Nucleotide Polymorphisms. Urology Journal, 2021, , 6337.	0.3	1
364	Prostate Cancer Genomics Research Disparities in Africa: Advancing Knowledge in Resource Constrained Settings. Cancer Control, 2022, 29, 107327482210959.	0.7	1
365	Comprehensive analysis of tumor mutation burden and immune microenvironment in prostate cancer. Clinical and Translational Oncology, 2022, 24, 1986-1997.	1.2	1
366	Family Socioeconomic Position and Lung Cancer Risk: A Meta-Analysis and a Mendelian Randomization Study. Frontiers in Public Health, 0, 10, .	1.3	3
367	Genomeâ€Wide 3â€²â€UTR Single Nucleotide Polymorphism Association Study Identifies Significant Prostate Cancer Riskâ€Associated Functional Loci at 8p21.2 in Chinese Population. Advanced Science, 2022, 9, .	5.6	3
368	African-specific molecular taxonomy of prostate cancer. Nature, 2022, 609, 552-559.	13.7	26
369	Testing the generalizability of ancestry-specific polygenic risk scores to predict prostate cancer in sub-Saharan Africa. Genome Biology, 2022, 23, .	3.8	16
370	Proteomics reveals MRPL4 as a highâ€risk factor and a potential diagnostic biomarker for prostate cancer. Proteomics, 2022, 22, .	1.3	2
371	How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis. Clinical Genitourinary Cancer, 2023, 21, 316.e1-316.e11.	0.9	4
372	Establishment of a <scp>fiveâ€enzalutamideâ€resistanceâ€relatedâ€geneâ€based</scp> classifier for <scp>recurrenceâ€free</scp> survival predicting of prostate cancer. Journal of Cellular and Molecular Medicine, 2022, 26, 5379-5390.	1.6	1
373	Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality. Clinical and Translational Medicine, 2022, 12, .	1.7	7
374	Prostate Cancer Transcriptomic Regulation by the Interplay of Germline Risk Alleles, Somatic Mutations, and 3D Genomic Architecture. Cancer Discovery, 0, , OF1-OF18.	7.7	2
375	French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease. Progres En Urologie, 2022, 32, 1275-1372.	0.3	15

#	Article	IF	Citations
376	Optimized high-throughput screening of non-coding variants identified from genome-wide association studies. Nucleic Acids Research, 2023, 51, e18-e18.	6.5	3
377	An integrated analysis of the cancer genome atlas data discovers a hierarchical association structure across thirty three cancer types. , 2022, 1, e0000151.		0
378	Genome-wide association study (GWAS) of circulating vitamin D outcomes among individuals of African ancestry. American Journal of Clinical Nutrition, 2023, 117, 308-316.	2.2	1
379	Haplotypic variants of COVIDâ€19 related genes are associated with blood pressure and metabolites levels. Journal of Medical Virology, 2023, 95, .	2.5	1
380	A multi-phenotype analysis reveals 19 susceptibility loci for basal cell carcinoma and 15 for squamous cell carcinoma. Nature Communications, 2022, 13, .	5.8	10
381	PQBP5/NOL10 maintains and anchors the nucleolus under physiological and osmotic stress conditions. Nature Communications, 2023, 14, .	5.8	3
382	Alteration of Lipid Metabolism in Prostate Cancer: Multifaceted Oncologic Implications. International Journal of Molecular Sciences, 2023, 24, 1391.	1.8	1
383	Systematic fine-mapping and functional studies of prostate cancer risk variants. IScience, 2023, 26, 106497.	1.9	1
384	Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry. European Urology, 2023, 84, 13-21.	0.9	12
387	An approach to genetic testing in patients with metastatic castration-resistant prostate cancer in Singapore. Annals of the Academy of Medicine, Singapore, 2023, 52, 135-148.	0.2	1
388	Malignant function of nuclear factor-kappaB axis in prostate cancer: Molecular interactions and regulation by non-coding RNAs. Pharmacological Research, 2023, 194, 106775.	3.1	4
401	Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nature Genetics, 2023, 55, 2065-2074.	9.4	4
404	Vitamin D and prostate cancer. , 2024, , 917-935.		0
407	Cancer Genetics Referrals and Management. , 2024, , 111-125.		0